Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1983 Sep;50(1):75–84.

Activation of the alternative complement pathway by natural antibody to glycolipids in guinea-pig serum.

N Okada, T Yasuda, T Tsumita, H Okada
PMCID: PMC1454237  PMID: 6193057

Abstract

Liposomes containing paragloboside (PG) on their membrane were readily lysed by C4-deficient guinea-pig serum (C4D-GPS) through activation of the alternative complement pathway (ACP). Therefore we examined the reactivity of several types of guinea-pig serum (GPS) on PG-liposomes and determined that all GPS except that from specific pathogen-free (SPF) Hartley guinea-pigs had lytic capacity in Mg-EGTA-GVB (gelatin veronal-buffered saline containing Mg++ and ethyleneglycol-bis(beta-aminoethyl ether)N,N'-tetraacetate). This lytic capacity of GPS corresponded with the amount of natural antibody to PG in those sera. Although GPS of SPF guinea-pigs (SPF-GPS) could not lyse PG-liposomes in Mg-EGTA-GVB, it could lyse the liposomes when heated C4D-GPS or Hartley GPS was added. Natural antibody to PG in the heated sera was regarded to have sensitized PG-liposomes to lysis by SPF-GPS via ACP activation. Since the antibody to PG-liposomes was removed by lacto-N-nor-hexaosylceramide which has the same chemical structure in the terminal oligosaccharide, the antibody to PG in GPS was suggested to have a specificity to the terminal structure of oligosaccharide shared by lacto-N-nor-hexaosylceramide. Furthermore, the IgM fraction, which had been prepared by gel filtration of heated C4D-GPS on a Sephadex G200 column, could also sensitize PG-liposomes to lytic reaction of SPF-GPS in Mg-EGTA-GVB. This sensitizing capacity of heated C4D-GPS was suppressed by absorption of the serum or its IgM fraction with anti-guinea-pig mu-chain antibody coupled to Sepharose. Therefore, it was concluded that the lysis of PG-liposomes by GPS in Mg-EGTA-GVB was a result of ACP activation mediated by natural antibodies to PG of the IgM type which are present in usual GPS. This conclusion indicated that natural antibodies of the IgM type might play a role with ACP in host defence, especially in C4-deficient guinea-pigs where the classical complement pathway is impaired.

Full text

PDF
75

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando S., Yu R. K. Isolation and characterization of a novel trisialoganglioside, GT1a, from human brain. J Biol Chem. 1977 Sep 25;252(18):6247–6250. [PubMed] [Google Scholar]
  2. Ehrnst A. Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway. J Immunol. 1978 Sep;121(3):1206–1212. [PubMed] [Google Scholar]
  3. Ensky J., Hinz C. F., Jr, Todd E. W., Wedgwood R. J., Boyer J. T., Lepow I. H. Properties of highly purified human properdin. J Immunol. 1968 Jan;100(1):142–158. [PubMed] [Google Scholar]
  4. Gadd K. J., Reid K. B. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J. 1981 May 1;195(2):471–480. doi: 10.1042/bj1950471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kasai M., Iwamori M., Nagai Y., Okumura K., Tada T. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol. 1980 Mar;10(3):175–180. doi: 10.1002/eji.1830100304. [DOI] [PubMed] [Google Scholar]
  6. Ledeen R. W., Yu R. K., Eng L. F. Gangliosides of human myelin: sialosylgalactosylceramide (G7) as a major component. J Neurochem. 1973 Oct;21(4):829–839. doi: 10.1111/j.1471-4159.1973.tb07527.x. [DOI] [PubMed] [Google Scholar]
  7. Moore F. D., Jr, Austen K. F., Fearon D. T. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J Immunol. 1982 Mar;128(3):1302–1306. [PubMed] [Google Scholar]
  8. NELSON R. A., Jr An alternative mechanism for the properdin system. J Exp Med. 1958 Oct 1;108(4):515–535. doi: 10.1084/jem.108.4.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Niemann H., Watanabe K., Hakomori S. Blood group i and I activities of "lacto-N-norhexaosylceramide" and its analogues: the structural requirements for i-specificities. Biochem Biophys Res Commun. 1978 Apr 28;81(4):1286–1293. doi: 10.1016/0006-291x(78)91275-5. [DOI] [PubMed] [Google Scholar]
  10. Nilsson O., Månsson J. E., Tibblin E., Svennerholm L. Gangliosides of human meconium - detection of a possible fetal antigen. FEBS Lett. 1981 Oct 26;133(2):197–200. doi: 10.1016/0014-5793(81)80504-2. [DOI] [PubMed] [Google Scholar]
  11. Okada N., Yasuda T., Okada H. Restriction of alternative complement pathway activation by sialosylglycolipids. Nature. 1982 Sep 16;299(5880):261–263. doi: 10.1038/299261a0. [DOI] [PubMed] [Google Scholar]
  12. Okada N., Yasuda T., Tsumita T., Okada H. Activation of the alternative complement pathway of guinea-gip by liposomes incorporated with trinitrophenylated phosphatidylethanolamine. Immunology. 1982 Jan;45(1):115–124. [PMC free article] [PubMed] [Google Scholar]
  13. Okada N., Yasuda T., Tsumita T., Okada H. Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine. Immunology. 1983 Jan;48(1):129–140. [PMC free article] [PubMed] [Google Scholar]
  14. Okada N., Yasuda T., Tsumita T., Shinomiya H., Utsumi S., Okada H. Regulation of glycophorin of complement activation via the alternative pathway. Biochem Biophys Res Commun. 1982 Sep 30;108(2):770–775. doi: 10.1016/0006-291x(82)90895-6. [DOI] [PubMed] [Google Scholar]
  15. PILLEMER L., SCHOENBERG M. D., BLUM L., WURZ L. Properdin system and immunity. II. Interaction of the properdin system with polysaccharides. Science. 1955 Sep 23;122(3169):545–549. doi: 10.1126/science.122.3169.545. [DOI] [PubMed] [Google Scholar]
  16. Polhill R. B., Jr, Newman S. L., Pruitt K. M., Johnston R. B., Jr Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J Immunol. 1978 Jul;121(1):371–376. [PubMed] [Google Scholar]
  17. Schenkein H. A., Ruddy S. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan. J Immunol. 1981 Jan;126(1):7–10. [PubMed] [Google Scholar]
  18. Schreiber R. D., Morrison D. C., Podack E. R., Müller-Eberhard H. J. Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med. 1979 Apr 1;149(4):870–882. doi: 10.1084/jem.149.4.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Seyama Y., Yamakawa T. Chemical structure of glycolipid of guinea pig red blood cell membrane. J Biochem. 1974 Apr;75(4):837–842. doi: 10.1093/oxfordjournals.jbchem.a130455. [DOI] [PubMed] [Google Scholar]
  20. Yasuda T., Naito Y., Tsumita T., Tadakuma T. A simple method to measure anti-glycolipid antibody by using complement-mediated immune lysis of fluorescent dye-trapped liposomes. J Immunol Methods. 1981;44(2):153–158. doi: 10.1016/0022-1759(81)90342-2. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES